Brain Implant for Neural Control of a Computer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01958086|
Recruitment Status : Recruiting
First Posted : October 8, 2013
Last Update Posted : July 25, 2019
|Condition or disease||Intervention/treatment||Phase|
|Quadriplegia||Device: Neural Communication System||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Feasibility Study for Use of a Brain Implant for Neural Control of a Computer|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||December 2020|
Experimental: Neural Communication System
The Neural Communication System consists of two Neuroport Arrays, which are descried in detail in the intervention description. Both Neuroport Arrays are inserted into Brodmann's Area 5 in the posterior parietal cortex, an area of the brain used in reach planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
Device: Neural Communication System
NeuroPort Arrays allow for the local recording of cerebral cortex. Key features include sterile, single use electrodes that provide access to a localized population of individual cells. The Neural Communication system is primarily composed of two NeuroPort Arrays. The main component of the NeuroPort Array is an array comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and has a platinum tip that is 100-200 microns in length. The Patient Pedestal is made from titanium and is 19 mm wide at the skin interface.
Other Name: NeuroPort Array
- Subject control of a tablet computer [ Time Frame: One year after array implantation ]Assessments will be compared with chance and previous reports of BMI efficacy using control signals derived from primary motor cortex. Computer-interface competency examination that measures the ability of the subject to control various aspects of the tablet user interface. Additionally we will measure the Quality of Life Inventory (QOLI) at regular intervals over the duration of the study. Changes in performance over time.
- Absence of infection or irritation [ Time Frame: One year after array implantation ]
The Serious Adverse event (SAE) rate will be calculated as the number of SAEs per implant-days. The SAE rate will be continuously compared to the 1% threshold level. CT scan; inspection of patient's scalp for evidence of reddening or discharge; review of new symptoms including possible fever, headache, visual or auditory changes, or change in mood or behavior; serial neurologic exams. The condition of the area will be compared with its condition on previous visits. History will be obtained regarding new symptoms.
Neurologic exam will be compared to baseline neurologic exam
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01958086
|Contact: Nader Pouratian, MD, PhD||310-206-2189||NPouratian@mednet.ucla.edu|
|Contact: Emily Rosario, PhD||909.596.7733 ext 3036||ERosario@casacolina.org|
|United States, California|
|University of California Los Angeles||Active, not recruiting|
|Los Angeles, California, United States, 90095|
|California Institute of Technology||Active, not recruiting|
|Pasadena, California, United States, 91125|
|Casa Colina Centers for Rehabilitation||Recruiting|
|Pomona, California, United States, 91769|
|Contact: Emily Rosario, PhD 909-596-7733 ext 3036 firstname.lastname@example.org|
|Principal Investigator:||Richard A Andersen, PhD||California Institute of Technology|
|Principal Investigator:||Nader Pouratian, MD, PhD||University of California, Los Angeles|
|Principal Investigator:||Emily Rosario, PhD||Casa Colina Hospital and Centers for Healthcare|